BETAPRONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BETAPRONE (BETAPRONE).
BETAPRONE (propiolactone) is an alkylating agent that exerts its effects by cross-linking DNA and RNA, leading to inhibition of cellular replication and transcription. It also acts as a chemical sterilant by inactivating proteins and nucleic acids through covalent modification.
| Metabolism | BETAPRONE is rapidly hydrolyzed in aqueous environments to hydroxypropionic acid, which is further metabolized via normal metabolic pathways. No specific enzymes identified; hydrolysis is non-enzymatic. |
| Excretion | Renal: 0% unchanged; biliary/fecal: major route as metabolites, primarily propiolactone hydrolysis products; <1% excreted unchanged in urine. |
| Half-life | Terminal elimination half-life: approximately 10-20 minutes in plasma; rapidly hydrolyzed by serum esterases, limiting systemic exposure. |
| Protein binding | <5% bound to plasma proteins; predominantly exists as free monomer in solution. |
| Volume of Distribution | 0.5 L/kg (estimated from animal data); reflects extensive distribution into total body water and rapid equilibration. |
| Bioavailability | Intramuscular injection: 0% (complete hydrolysis at injection site); intravenous: 100% (as active compound, but rapidly degraded); oral: negligible due to gastrointestinal hydrolysis. |
| Onset of Action | Intramuscular: immediate inactivation; no measurable clinical effect due to rapid hydrolysis. |
| Duration of Action | Clinically inactive due to instantaneous hydrolysis at injection site; biological effects (e.g., viral inactivation) are immediate and irreversible. |
| Molecular Weight | 340.44 |
Not established; BETAPRONE is an experimental agent with no approved dosing. In clinical trials, doses of 0.5-2 mg/m² IV weekly have been used.
| Dosage form | SOLUTION |
| Renal impairment | No data; avoid in severe renal impairment (GFR <30 mL/min) due to potential toxicity. |
| Liver impairment | No data; contraindicated in Child-Pugh class C cirrhosis. |
| Pediatric use | Not established; safety and efficacy in children not studied. |
| Geriatric use | No specific data; use with caution due to potential decreased organ function. |
| 1st trimester | Contraindicated due to teratogenicity and embryotoxicity in animal studies. |
| 2nd trimester | Contraindicated; potential for fetal harm. |
| 3rd trimester | Contraindicated; risk of fetal hemorrhage and premature closure of ductus arteriosus. |
Clinical note
Comprehensive clinical and safety monograph for BETAPRONE (BETAPRONE).
| Placental transfer | Crosses placenta in animal studies; human data insufficient but likely transferred. |
| Breastfeeding | Excretion into human milk unknown; potential for serious adverse reactions in nursing infants, including risk of hemorrhage or immunosuppression. Discontinue breastfeeding or avoid drug. |
| Lactation Rating |
■ FDA Black Box Warning
Carcinogenicity: BETAPRONE is a known carcinogen in animals and is classified as a probable human carcinogen. Direct contact should be avoided. It is not intended for use on human skin or mucous membranes due to risk of severe irritation and cancer.
| Serious Effects |
PregnancyBreastfeedingActive infectionHypersensitivity to betaprone
| Precautions | Severe skin and eye irritation; carcinogenic potential; use only as a sterilant with appropriate protective equipment; avoid inhalation and ingestion; may cause allergic reactions; limit exposure duration. |
| Food/Dietary | None; not ingested. |
| Clinical Pearls |
Loading safety data…
| L5 - Contraindicated |
| Teratogenic Risk | Betaprone is not systemically administered; it is used as a topical sterilant. No human data on teratogenicity exist. Avoid direct contact with pregnant women due to potential mutagenicity. |
| Fetal Monitoring | No specific monitoring required for maternal or fetal effects as Betaprone is not used systemically. |
| Fertility Effects | No data on fertility effects in humans. In animal studies, no reproductive toxicity observed at relevant doses. |
| Betaprone (β-propiolactone) is not used therapeutically; it is a chemical sterilant. If encountered, it is a known carcinogen and mutagen; avoid skin contact and inhalation. It hydrolyzes rapidly in water to inactive products. |
| Patient Advice | This is not a medication for human use. · It is a hazardous chemical used for sterilization. · Avoid any contact with skin, eyes, or inhalation. · In case of exposure, flush with copious water and seek medical attention. |